SKAI: Talking with parents about human papillomavirus (HPV) vaccination

This recently published conversation guide aims to help immunisation providers engage confidently with parents and carers about the importance of timely human papillomavirus (HPV) vaccination.

Sharing Knowledge About Immunisation (SKAI): Talking with parents about human papillomavirus (HPV) vaccination 

To learn more about HPV, visit MVEC: HPV. 


TGA: 2026 Seasonal Influenza Vaccines

On 4 March, the Therapeutic Goods Administration (TGA) published its 2026 Seasonal Influenza Vaccines report. 

The report covers the 2026 seasonal influenza vaccines, with information on vaccines by age group, vaccine ingredients and co-administration. 

For more information, visit MVEC: Cúm.


ATAGI: Statement on the administration of seasonal influenza vaccines in 2026

On 27 February, the national Department of Health and Aged Care released the ATAGI statement on the administration of seasonal influenza vaccines in 2026.

Influenza vaccines are recommended annually and are funded on the National Immunisation Program (NIP) for:

  • children aged 6 months to less than 5 years 
  • all adults aged 65 years and older 
  • specific populations aged 5 to 64 years who are at greatest risk of developing complications from influenza infection (including pregnant women, First Nations people, and those with certain medical risk factors). 

For more details, refer to ATAGI’s full statement, and MVEC’s influenza reference page which has been updated for the 2026 influenza season. 


The Guardian: FDA reverses course and will review Moderna’s mRNA-based flu vaccine

Following backlash after it initially refused to review Moderna’s mRNA influenza vaccine, the US Food and Drug Administration (FDA) will now review the vaccine.

Moderna submitted an application for the FDA to approve the new product in December 2025. Other countries, including Australia, accepted the vaccine for review. The FDA’s initial refusal to review the vaccine sparked concerns about the influence of the current administration.

Read the full article at The Guardian: FDA reverses course and will review Moderna’s mRNA-based flu vaccine.


Về MVEC

Trung tâm Giáo dục về Vắc xin Melbourne (MVEC) là một trang web giáo dục, được phát triển với mục đích cung cấp thông tin tiêm chủng cập nhật cho cả các chuyên gia chăm sóc sức khỏe và người dân. Chúng tôi có trụ sở tại Viện Nghiên cứu Trẻ em Murdoch (MCRI), một tổ chức nghiên cứu và có liên kết với SAEFVIC (Giám sát các Sự kiện Bất lợi Sau khi Tiêm chủng trong Cộng đồng), Dịch vụ An toàn Vắc xin Victoria.